Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 
 
Secure Logon Learn More 
* For Financial Representatives *
and Operations Personnel Only
User Id:
Password:
 
Help, I Forgot My Password!
Benefits of Registration

Commentary
Subscribe to First Trust commentary and analysis.

Bob Carey
Chief Market Strategist
Blog
Brian Wesbury
Chief Economist
Blog
Investment Insights
FINRA's BrokerCheck
Check the background of
First Trust using FINRA's BrokerCheck.
Factoid of the Day Friday, August 18, 2017
Bloomberg data indicates that global biotechnology mergers and acquisitions (M&A) activity has slowed, with just $11.5 billion in announced deals thus far in 2017, according to FierceBiotech. In 2015 and 2016, biotech M&A deal volume topped $30 billion. One reason cited for the sluggish activity is some CEOs waiting to see if President Trump's tax reform policies are enacted. Another is that valuation levels for many biotechs are high. Big Pharma CEOs have stated that they are currently seeking smaller deals. 
 
Brian Wesbury - Economic Video Commentary
North Korea and Stocks

Bob Carey - Video Market Update
Strong Earnings Push Markets Higher

New ETFs - Listing Date: August 9, 2017
First Trust Dow 30 Equal Weight ETF (EDOW)
• Investor Guide • Press Release  • Fund Information

  Unit Investment Trusts Upcoming Deposit Information Initial Offer Date
  Click Here  for CUSIP Information.

Deep Value Dividend, 16 8/21/2017
International Capital Strength, 35 8/21/2017
SMid Capital Strength, 35 8/21/2017
Equity Income Select, 54 8/23/2017
Equity Income, 57 8/23/2017
Stonebridge Preferred Income, 14 8/23/2017
European Deep Value Dividend, 16 8/25/2017
Sabrient Rising Rate, 6 8/25/2017
Global Dividend, 52 8/28/2017
SMid High Dividend, 27 8/28/2017
Balanced Income, 58 8/30/2017
Municipal Income Closed-End, 71 8/30/2017
Municipal Income Opportunities Closed-End, 45 8/30/2017
Balanced Income Equity and ETF, 28 8/31/2017
Municipal Advantage Closed-End and ETF, 43 8/31/2017
First Trust Mobile
Learn about our Mobile SiteGet the latest First Trust product and research information on your smartphone or tablet device!
Learn more...

Institutional Investors
Unit Investment Trusts
Variable Annuities
Closed-End Funds
Exchange-Traded Funds
Open End Mutual Funds

Structured Products
Seperate Managed Accounts

401k

First Trust Indexes
 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2017 All rights reserved.